Pacira BioSciences
PCRX
262 hedge funds and large institutions have $2.99B invested in Pacira BioSciences in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 95 increasing their positions, 84 reducing their positions, and 30 closing their positions.
99% more call options, than puts
Call options by funds: $6.13M | Put options by funds: $3.09M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 84
1.49% less ownership
Funds ownership: 113.64% → 112.14% (-1.5%)
3% less funds holding
Funds holding: 270 → 262 (-8)
14% less capital invested
Capital invested by funds: $3.49B → $2.99B (-$500M)
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$31.9M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$26.8M |
| 3 |
Two Sigma Advisers
New York
|
+$19.2M |
| 4 |
Two Sigma Investments
New York
|
+$17.6M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$49M |
| 2 |
BlackRock
New York
|
-$32.6M |
| 3 |
D.E. Shaw & Co
New York
|
-$27.6M |
| 4 |
Renaissance Technologies
New York
|
-$16.1M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$14.3M |
PCRX Hedge Fund Activity: Q2 2021 in Review
262 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2021, worth a combined $2.99B — down 14% from $3.49B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PCRX and 24 opened new positions — a net loss of 6 holders — while 84 trimmed existing stakes and 95 added.
The largest buyer was Westfield Capital Management, adding an estimated $31.9M. The largest seller was Wells Fargo, cutting an estimated $49M.
- 262 institutional investors held Pacira BioSciences (PCRX) as of Q2 2021, down from 270 in Q1 2021.
- Funds reported $2.99B of Pacira BioSciences stock for Q2 2021, down 14% quarter-over-quarter.
- 24 funds opened new Pacira BioSciences positions in Q2 2021 and 30 closed out, a net change of -6 holders.
- The largest Pacira BioSciences buyer in Q2 2021 was Westfield Capital Management, an estimated $31.9M added.
- The largest Pacira BioSciences seller in Q2 2021 was Wells Fargo, an estimated $49M sold.
Based on aggregated 13F filings for Q2 2021.